{'fraction_non_alphanumeric': 0.02158273381294964, 'fraction_numerical': 0.005275779376498801, 'mean_word_length': 5.302114803625377, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Beyond the membrane--the role of new PD solutions in enhancing global biocompatibility.

Since the introduction of continuous ambulatory peritoneal dialysis (CAPD) during the late 1970s as a form of home-based, self-care renal replacement therapy, peritoneal dialysis (PD) has become an appealing alternative for the treatment of patients with end-stage renal disease (ESRD). A significant amount of research over the last 25 years has resulted in continuous improvements in the quality of PD treatment. Survival of patients on PD is now at least as good as with hemodialysis, especially during the first years of treatment, and results are gradually improving. Considerable progress has been made in understanding the nature of the interactions between the dialysis solution and the peritoneal membrane, how these interactions may result in structural alterations to the membrane, and how peritoneal solute and fluid transport are influenced by these alterations. During recent years, as PD technique survival has improved and peritonitis rates declined, PD researchers have focused more attention on ways to improve the biocompatibility of dialysis solutions with the goal of extending the life of the peritoneum as a dialyzing membrane, which may improve and extend the life of the PD patient. The reason for this research focus is the observation that the characteristic structural and functional alterations to the peritoneal membrane during long-term PD treatment may be the consequence of the continuous exposure to solutions with high concentrations of glucose, glucose degradation products (GDPs), and lactate, low pH, and high osmolality. It is now clear that these alterations to the peritoneal membrane may have a profound effect on the well-being of the patient on long-term PD therapy. According to the Consensus Conference on Biocompatibility held in 1994 [1], biocompatibility is “the ability of a material, device or system to perform without a clinically significant host response in a specific application.” When applied to PD, biocompatibility refers to the ability